SEC Form 4 · accession 0001209191-17-016324
REATA PHARMACEUTICALS INC · RETA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
William D. McClellan Jr.
Director
Period of report
Mar 1, 2017
Accepted (ET)
Mar 2, 2017 · 11:50 am EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001358762
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1,F2 | $26.46 | Mar 1, 2017 | A | 12,000 | A | — | Mar 1, 2027 | Class B common stock | 12,000 | 12,000 | D |
| Stock Option (right to buy)F3,F2 | $26.46 | Mar 1, 2017 | A | 1,500 | A | — | Mar 1, 2027 | Class B common stock | 1,500 | 1,500 | D |
Explanation of responses
- F1The options vest in 3 equal installments on March 1, 2018, March 1, 2019 and March 1, 2020, subject to continued service through each vesting date.
- F2The Class B common stock is convertible into Class A common stock on a one-for-one basis at the holder's election at any time. The conversion right of the Class B common stock has no expiration date.
- F3The options vest in 1 installment on June 1, 2017, subject to continued service through such vesting date.